At the world's largest oncology conference, Pfizer is arriving with one of its most ambitious scientific programs in years. The American Society of Clinical Oncology Annual Meeting, running from May 29 through June 2, 2026, in Chicago, serves as the global showcase for cancer medicine, and Pfizer has made it a centerpiece of its reinvention as an AI-integrated pharmaceutical company. With a pipeline spanning lung, breast, colorectal, prostate, and skin cancers, the company is demonstrating what happens when machine learning meets decades of biological expertise.

What Pfizer Is Presenting at ASCO 2026

Pfizer will present new data across its oncology pipeline and portfolio at the ASCO Annual Meeting, with data from more than 40 company-sponsored, investigator-sponsored, and collaborative research abstracts, including three late-breaking sessions and eight oral and rapid oral presentations. These data highlight Pfizer's leadership in establishing potential new standards of care across multiple cancer types and its next-generation pipeline of novel targets and combination strategies designed to extend impact into broader patient populations and earlier lines of therapy.

Jeff Legos, Chief Oncology Officer at Pfizer, framed the company's presence with a clear statement of intent. Legos said that for people living with cancer and their families, every moment matters, and that Pfizer is moving with urgency to drive advances that have the potential to change standards of care and bring new, innovative options to patients in earlier lines of therapy.

Key pipeline candidates and clinical data being shared at ASCO 2026:

• Updated results from a Phase 1 study of sigvotatug vedotin, a novel integrin beta-6-directed antibody-drug conjugate, in combination with pembrolizumab in non-small cell lung cancer, supporting the ongoing SigVie-003 Phase 3 study of the combination in first-line settings and SigVie-002 evaluating the drug as monotherapy in previously treated advanced NSCLC patients.
• First results from a Phase 2 study of neoadjuvant atirmociclib, a highly selective CDK4 inhibitor, in combination with letrozole versus letrozole alone in hormone receptor-positive, HER2-negative breast cancer, with atirmociclib being developed as a potential first-in-class next-generation cell cycle inhibitor backbone for this cancer type in both early adjuvant and first-line metastatic settings.
• A late-breaking Phase 3 presentation from the TALAPRO-3 study highlighting clinically meaningful radiographic progression-free survival benefit for Talzenna plus Xtandi in metastatic castration-sensitive prostate cancer patients with homologous recombination repair gene alterations, with effects consistent across subgroups and a strong overall survival trend.
• Findings from a Phase 1b study of brain-penetrant MEK inhibitor polfurmetinib in combination with next-generation BRAF inhibitor claturafenib in advanced BRAF-mutant melanoma, reflecting the company's push into targeted combination strategies for genetically defined solid tumors.

How AI Is Driving Pfizer's Oncology Research

The data being presented at ASCO does not exist in isolation from Pfizer's broader technology transformation. The company has methodically embedded artificial intelligence into the chemistry and biology of how it discovers and develops cancer drugs, and the pipeline on display in Chicago is in part a product of that investment.

Pfizer CEO Albert Bourla said that the main lever behind the company's productivity gains was the successful deployment of AI, adding that Pfizer did not just cut costs but improved productivity, with AI engineers now being recruited and embedded across discovery, medical regulatory, safety, pharmacovigilance, and clinical trial execution to measure success, productivity, speed, and costs.

Pfizer has paid up to $350 million to PostEra since 2020 for AI-designed small molecules and antibody-drug conjugate payloads, and in January 2026 announced a strategic collaboration with the Boltz biomolecular foundation model team to refine open-source models on Pfizer's internal data.

PostEra's platform, Proton, uses generative chemistry and synthesis-aware design to advance drug programs including small molecule therapeutics and ADCs, and PostEra co-founder Alpha Lee confirmed that one compound went from a cold start to in vivo proof of concept in about eight months using the AI-driven approach.

Pfizer plans to spend $11 billion on R&D activities in 2026, with the company's chief scientific officer Chris Boshoff stating that the AI integration is enabling the company to be more productive in R&D infrastructure and take on more substrate to focus on creating medicines for the end of the decade and beyond.